Chief.AI secures £370k Grant funding from InnovateUK

‘Pay as you go’ Artificial Intelligence

Chief.AI and Medicines Discovery Catapult awarded funding to make AI accessible to all drug discovery researchers

Today [1 May 2019], Artificial Intelligence (AI) in drug discovery gains further support as Chief.AI and Medicines Discovery Catapult secure a grant from Innovate UK to make AI accessible to all drug discovery researchers.

This partnership will address the need for more accessible AI and data in the B2B marketplace – prioritising drug discovery, diagnostics and clinical trials markets.

By providing easy access to scarce but invaluable, cutting edge skills, resources and expertise, the platform will enable UK SMEs to leverage the power of AI at the click of a button, reinvigorating drug discovery by indirectly contributing to novel new drugs, treatments and diagnostics.

Users will be able to search by sector and/or keyword to discover and connect their own machine and database to the relevant AI algorithm on a pay as you go, on demand basis.

£370k funding will enable Chief.AI to create their searchable online platform, providing researchers with access to downloadable, off-the-shelf AI models, algorithms and high-quality data. Thus, connecting customers to suppliers in a secure, private environment, deriving revenue via commission and cloud provider charges.

Medicines Discovery Catapult will support the development of high-quality datasets and plan to provide exclusive access via the Chief.AI platform to their own novel AI algorithms; state-of-the-art image processing models capable of extracting information from pharmacological data and medical images in scientific journal papers to predict a potential drug targets performance.

The platform will be enriched through a comprehensive rating, benchmarking, pricing and scoring system and provide tailored sector relevant services as opposed to a one stop shop. Each AI algorithm will be further validated by customer use and experience.

New models for drug discovery are desperately needed. Around 90% of potential drug candidates fail and the cost of failure is enormous, ranging from $800m to $1.4bn[1]. For drugs targeting complex and poorly understood conditions, failure is near certain.

AI has the potential to solve many of the underlying issues with drug discovery. For example, deep learning algorithms could analyse molecules and predict how they might act in the human body at an earlier stage than in the traditional drug discovery process, potentially saving £billions in needless R&D and clinical trials

A number of companies are developing AI services and investment in AI for drug discovery is surging. However, lack of expertise and lack of knowledge about available services is a barrier to uptake. Furthermore, lack of sufficient high-quality structured and standardised data represents a major challenge in the implementation of AI.

Professor John Overington, Chief Informatics Officer of Medicines Discovery Catapult, says:

“This partnership and funding clearly indicate the importance and value of artificial intelligence as a new approach to support UK SMEs and reinvigorate drug discovery. Our aim is to help deliver a platform which is of high value to UK SMEs to advance their own drug discovery projects faster and more efficiently by accessing otherwise inaccessible, complex technical expertise”

Waqar Ali, Founder of Chief.AI says:

“The UK is where the first industrial revolution began, and we now want to accelerate AI provision throughout the world to become one of the biggest industrial force

multipliers of the twenty first century. Chief.AI will make the discovery of drugs more efficient, at lower cost and will diagnose diseases earlier to enable better outcomes.”

Dr Kath Mackay, Director – Ageing Society, Health & Nutrition, Innovate UK says:

“Harnessing the capabilities of AI in medicine and in other fields is a key component of the government’s modern industrial strategy. Innovate UK’s support for Chief.AI and Medicines Discovery Catapult will help to allow SMEs to work more efficiently and rapidly in the realm of drug discovery. This will lead to real benefits for patients and help expand and grow this vital sector.”

The capabilities of AI are predicted to drive Global GDP upwards of 14% by 2030[2], resulting in a total gain of $15.7 trillion2due to productivity and personalisation improvements. In the UK, the gain is predicted to be as large as 5% of GDP[3], and extra spending power per household of up to £1,800-£2,300 a year by 20303.





OpusVL led consortium secures £790k Grant funding from Innovate UK.

Leading UK Open Source software integrator, OpusVL, today announced that its consortium has been awarded a £790,000 government grant to develop re-usable Open Source applications for the UK healthcare sector. The sum is the largest Innovate UK research and development grant awarded to an Open Source project1.

The grant is for the development of processes for creating and delivering Open Source software to the UK healthcare sector as part of a wider open approach, aligned with the mandate of the new NHSx2 government department. The project includes proof of concept through the creation and validation of an app that calculates the National Early Warning Score, a key predictor of sepsis in hospital patients, which claims the lives of an estimated 46,000 people a year3 in the UK.

The 19-month project will research and implement a new digital electronic observation (eObs) solution to identify deteriorating patients. Notably, not only does the solution connect through open standards to other hospital systems, the software, design, documentation and all associated components will be made available to the community to be studied, re-used and further developed.

Its ultimate aim is to create a blueprint for clinician-led open software design that delivers the exact functionality – with future flexibility and integrated in to the NHS networks – needed to optimise NHS patient care, while reducing the NHS’s £7bn annual software licence renewal bill.

The ground-breaking practical study will work with doctors and nurses to evaluate current NHS working practices, identifying strengths and weaknesses. A best practice approach will then be implemented in the app, before being tested in a cutting-edge hospital simulator. The last stage of the project will be field trials at hospitals in two NHS Trusts, before the final report is delivered.

OpusVL is the lead partner in the consortium, joined by the South London and Maudsley NHS Foundation Trust, Cheshire and Wirral Partnership NHS Foundation Trust, The Apperta Foundation CIC Trust, Open UK and a leading UK University. The combination of academic rigour, clinical partnership and technological expertise harnessed by the consortium for this study heralds a turning point in the NHS’s approach to open source software.

Stuart J Mackintosh, CEO of OpusVL said, “We’re thrilled to have been given the opportunity by Innovate UK to prove that professional open source is the only viable solution to the NHS’s complex software needs. Innovate UK understood that we have ambitious aims to transform the NHS’s approach to digital technology, helping to create software that is the perfect clinical fit for today and adaptable for tomorrow saving lives and money simultaneously.”

The project launches on 1st April , with trials due to start in May 2020. Project progress will be presented at key UK healthcare events with final research findings published in August next year.

For more information please contact: Lauren Westley, OpusVL, 01788 298456


  • OpusVL is the UK’s most established Open Source software integrator, solving business problems with world-class Open Source digital technology solutions.
  • Celebrating 20 years in business in 2019, OpusVL was founded by Stuart J Mackintosh and now employs over 25 talented staff at its headquarters in Rugby, Warwickshire.
  • OpusVL helps customer meet their goals by developing and supporting perfectly tailored, flexible open software, free of costly licence renewal fees. Its customers are organisations in the private and public sectors whose needs are not being met by ‘off the shelf’ solutions and those who wish to break free of the limitations and high costs of proprietary software. For further information, please visit
  • The Apperta Foundation CIC Trust is a clinician-led, not-for-profit company. Supported by NHS England, NHS Digital and others, it promotes open systems and standards for digital health and social care. Apperta shows how the delivery of health and social care can be
  • transformed when data, information and knowledge in IT systems is open, shareable and
  • computable. For more information, visit
  • South London and Maudsley NHS Foundation Trust provides the widest range of NHS mental health services in the UK. For further information, visit
  • Cheshire and Wirral Partnership NHS Foundation Trust provides mental health, learning
  • disability and community physical health services. For further information, visit
  • OpenUK is the UK open source industry association representing the open source business
  • community across the UK and focused on stimulating the professional UK supply chain. For further information, visit

Mogrify subsidiary Chondrogenix secures funding from SBRI

Healthcare to advance regenerative cartilage therapy to the clinic Chondrogenix will use Mogrify’s data-driven conversion platform to generate a safe, efficient and scalable source of cartilage cells for the treatment of osteoarthritis

Cambridge, UK, 1 st April 2019: Chondrogenix, a wholly owned subsidiary of Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies, today announced that it has secured funding from SBRI Healthcare, the NHS England funded initiative championed by the AHSN Network, to develop a safe, efficient and scalable source of therapeutic cells for the treatment of osteoarthritis.

The Mogrify Platform (Rackham et al., Nature Genetics, 2016) has been used by Chondrogenix to successfully convert multiple starting cell types to functional chondrocytes capable in vitro of spontaneously forming cartilage, and this funding will support the partnering of this asset to take it through the remaining pre-clinical stages before entering clinical trials.

Osteoarthritis is a progressive disease of synovial joints resulting in the breakdown of articular cartilage and bone and is the most common joint disorder, affecting more than 30 million adults in the United States* alone. Current treatments only focus on addressing the symptoms, for instance, pain or inflammation, and in some cases result in total joint replacement.

Following on from a proof-of-concept study, Chondrogenix is using a cocktail of small molecules (identified by the Mogrify Platform) to transdifferentiate several different starting cell types, directly sourced from diseased patients, into functional hyaline chondrocytes to ultimately be used in the clinic to enhance the already approved Autologous Chondrocyte Implantation (ACI) therapy and create additional allogeneic and in vivo reprograming therapies. Chondrogenix will apply for the Phase 2 funding from SBRI Healthcare for £1 million GBP, which will support the progression of the Company’s lead asset into the clinic.

Dr Wael Kafienah, PhD, Director, Chondrogenix and Senior Lecturer, University of Bristol, said: “After several years of research in collaboration with Mogrify, it is great to see our transdifferentiated cartilage cells gain commercial traction from grants such as the SBRI Healthcare and (pre-)clinical partners.”

Pierre-Louis Joffrin, Corporate Development Executive, Mogrify, said: “Having started from various cell types, the produced chondrocytes are displaying all of the markers necessary for use as both autologous and allogeneic therapies which would represent a huge advancement in the standard of care of osteoarthritis. We are speaking with a number of commercial partners and clinical development specialists, and our focus is on bringing a new therapy to market to improve the lives of osteoarthritis

*Centers for Disease Control and Prevention

Rackham OJL et al. A predictive computational framework for direct reprogramming between human cell types. Nature Genetics. 2016 Mar;48(3):331-5. doi: 10.1038/ng.3487. Epub 2016 Jan 18.

For further information please contact:

Pierre-Louis Joffrin
Zyme Communications
Lorna Cuddon
Tel: +44 (0)7811 996 942

Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.

The platform takes a systematic big-data approach to identify, from next-generation sequencing and gene-regulatory networks, the transcription factors (in vitro) or small molecules (in vivo), needed to convert a cell. By bypassing the stem cell-stage of cell transformation, Mogrify simultaneously addresses challenges associated with efficacy, safety and scalability.

Mogrify is applying its patented technology to generate IP and cell types that will power the development and manufacture of new cell therapies across every therapeutic area. Uniquely positioned to address a cell therapy market estimated to be $35 billion USD by 2023, Mogrify is commercializing its technology via IP licensing, product development, and drug development. Based in Cambridge, UK, the Company has raised $3.7 million USD seed funding from Ahren Innovation Capital, 24Haymarket and Dr Darrin M Disley, OBE.

Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify

About Chondrogenix

Chondrogenix is a private biotechnology company based in the UK. Our founders are experts in cell engineering, bioinformatics and computational genomics and founded the company with the mission of revolutionizing the way that cell reprograming is utilized in osteoarthritis.

The company’s unique combination of skills has allowed us to find ways to precisely control the cellular fate of chondrocytes. We are using this knowledge to pioneer a novel first-in-class cartilage regenerative medicine. This new data-driven approach to the field of regenerative medicine allows us to find optimal treatment strategies without the need for costly trial and error optimization.

About SBRI Healthcare
SBRI Healthcare is an NHS England initiative, led by the Academic Health Science Network (AHSN), who aim to promote UK economic growth whilst addressing unmet health needs and enhancing the take up of known best practice.

HealthTech company Cog-Neuro Speech Therapy secures £85k Grant and Debt finance from InnovateUK and Development Bank of Wales

People suffering with communication difficulties are benefitting from a new speech therapy service that has been developed by Caerphilly-based Cog-Neuro Speech Therapy Limited.

With a £25,000 loan from the Development Bank of Wales and a £60,000 grant from Innovate UK, the mobile application has been developed to help people with communication difficulties to regain their ability to communicate, maintain relationships and re-integrate into the community. 

Cog-Neuro was first established by speech therapist Sheiladen Montero Aquino in 2012. She has now developed an application that will enhance speech therapy service for people with communication difficulties following a stroke, brain injury, and other progressive neurological disorders including Parkinson’s disease and Multiple Sclerosis.

By using the application, patients can access services during the time when they are most stimulable for rehabilitation or while waiting for a speech therapy appointment from the NHS. Patients and their families who want intensive speech therapy can also use the app alongside speech therapy sessions to support their current rehabilitation program.

The Cog-Neuro application focuses on five areas of language including listening, speaking, reading, writing and thinking (semantics). Gamification and stealth learning has been used to encourage interactivity and concentrated attention, which have been shown to be key factors in neuroplasticity and brain regeneration.

Mini-games target specific linguistic skills with visual instructions and trial options at the start of each game. Feedback is given to users. In addition, each of the games has three levels of difficulty depending on the user’s  progress. At the end of the game a report is generated which can be sent via email. It is also possible to customise the game for the client.

Sheiladen Montero Aquino founder of Cog Neuro said: “Throughout my international practice in speech therapy, I have wanted to develop an innovative treatment that will help people communicate again after a stroke, brain injury, Parkinson’s or Dementia.

“The Innovate UK funding helped develop the mobile software but we still needed additional finance. Business Wales introduced me to Rhiannon Brewer at the development bank – she understood our business and showed a sincere desire for our success.  She guided me through the process and we received the funds promptly. We found a reliable partner for this journey!

“I’m grateful to the Development Bank of Wales, Business Wales and Innovate UK for their excellent support throughout.”

Rhiannon Brewer, Senior Investment Executive with the Development Bank of Wales said: “Working in partnership with other funders and business support organisations to help ambitious and passionate business owners to succeed is what we do best. Each company we work with is different and every deal is bespoke. So, I was particularly pleased  to work with Business Wales and Innovate UK to offer a funding package that really is making a difference to the business whilst improving people’s lives.

“The new product from Cog-Neuro will help to benefit some of the 15,500 people in Wales who are estimated to suffer with severe speech and communication problems. It’s very rewarding to know that our micro loan is now helping to ensure that people will receive the care  they need to support independence and quality of life.”

David apjohn-Williams, Business Wales Regional Manager for South Wales, said: “As well as supporting entrepreneurs and SMEs across Wales to start and expand, collaborating with other support organisations and stakeholders to offer a holistic approach that is tailored to the individual, is paramount to us.

“I am delighted that, together with the Development Bank of Wales and Innovate UK, our advisers were able to support Sheiladen and Cog Neuro to create a robust financial plan and secure the micro loan, as the business continues to develop their life-changing projects.”

The Development Bank of Wales offers micro-loans from £1,000 to £50,000 as well as loans and equity up to £5 million.

UK AI companies Biorelate and Intellegens win share of £20m in Innovate UK grant competition to explore creation of advanced data curation tool

2019-02-18. Manchester, UK and Cambridge, UK. Two artificial intelligence (AI) companies, Biorelate Limited and Intellegens Limited, today announced their success in the third round of the Innovate UK open grant funding competition. Together, the two companies have secured over £300,000 from Innovate UK and will co-invest an additional £130,000 to deliver a partnership project entitled: “Chemeia: A synergistic AI integrated architecture for augmenting high-value dark-data”.

Project Chemeia (‘Chem-ee-a’) will test the potential for combining the capabilities of Biorelate’s deep text mining (Galactic AITM) technology with Intellegens’ sparse data solution, to produce up to date, comprehensive, and reliable data sets for high-value R&D work.

Biorelate and Intellegens are two high-technology companies specialising in the development and application of novel AI techniques that can solve common problems associated with optimising data curation for R&D.

Data curation is a critical component of scientific research and development (R&D) in many areas including biological research and advanced materials manufacturing – helping to ensure that results from in-house experiments and information from external sources can be integrated for further analysis.

Current AI methods for curating scientific experimental data can be slow and are prone to leaving gaps in the information they produce. Existing techniques are costly to deploy at scale. Estimates suggest that around 80% of published scientific literature is unused and the effort of data curation is an obstacle to research. This project will determine how modern AI approaches can make this better.

Biorelate CEO and founder Dr Daniel Jamieson said ‘Adequate data curation underpins so much of the future success of research and development in science and Biorelate is continually investing in innovative ways to improve this. What really excites me about this project is the prospect of bringing two completely different, game-changing technologies together to achieve something entirely novel. We can’t wait to start!’

Intellegens CEO and co-founder Ben Pellegrini said ‘We are excited to work with the team at Biorelate to bring together the best parts of our AlchemiteTM platform with Galactic AITM. Independently, our AI technologies are proven; together they have the potential to take the pain out of data curation. Biorelate curates databases from the analysis of published scientific literature – allowing researchers to extract structured biological knowledge for use in a variety of applications. We work with sparse data, using our deep learning algorithm to make accurate predictions in datasets that are as little as 0.05% complete. With the funding granted by Innovate UK we’ll be able to exploit the synergies between these two approaches and see if it is possible to create a powerful new approach that can transform data curation.”

Both CEOs agreed that ‘Funding from Innovate UK has made this project possible. This support will help us contribute to the UK’s position as a leading nation in this field.’

Biorelate, Manchester Science Park, Manchester, UK, M15 6JJ

Biorelate is developing Galactic AITM, an advanced text analytics & data mining cloud-based platform. Galactic reduces research risks, increases commercial awareness and helps solve biomedical research’s greatest challenges.

Intellegens, Eagle Labs, 28 Chesterton Road, Cambridge, Cambridgeshire, United Kingdom, CB4 3AZ

Intellegens have developed Alchemite, which builds on existing numerical curated resources (sparse data) by using AI to predict ranked unknown data-points and uncertainties. No other solution on the market can replicate Alchemite’s low cost modelling, prediction, error detection & parameter optimisation for big, sparse, numerical data.

Innovate UK, the UK’s innovation agency

Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation.

LettUs Grow wins £45,000 from Vodafone

LettUs Grow, creator of advanced aeroponic technology and farm management software for indoor farms, has been named one of the UK’s top tech startups at the Vodafone Techstarter awards and won £45,000.

The programme celebrates startups developing and using technology as a force for good. It aims to uncover and develop ideas that harness the power of technology to improve health, education, environmental protection or social mobility.

LettUs Grow will receive £45,000 alongside a 12-month programme of support from Vodafone and the Social Tech Trust – an investor in socially motivated tech.

Humanity must increase food production by 70% to feed an extra 2 billion people by 2050. We must do this with 25% less farmland, depleted soils and an increasingly unstable climate.

To address this problem, LettUs Grow has designed a patent-pending aeroponic system that has shown growth rate increases of over 70% compared to existing solutions for a number of crops. Instead of using soil or water, plant roots are suspended in a nutrient-dense mist. This results in faster growth rates than conventional field growing or hydroponics, consistent and predictable year-round harvests, and a 95% reduction in water usage versus open-field agriculture.

Farms don’t need to use pesticides or herbicides when using LettUs Grow’s technology and by siting farms in densely populated areas, they can reduce the environmental impact of delivering food from plot to plate.

Jack Farmer, one of LettUs Grow’s three founders and operational lead, said: “We’re excited to be working with Vodafone.

“We are very keen to collaborate with them from a technical and a commercial standpoint. That mentorship is really going to help us develop our business.

“We are looking to work with Vodafone and a number of other key partners this year, to implement our hardware and software and deliver profitable pilot farms – in greenhouses, research centres and vertical farms – before then working with these partners to scale nationally and internationally.”

Nick Jeffery, chief executive, Vodafone UK, commented: “The range and calibre of the Vodafone Techstarter winners show that the UK is home to a thriving social tech sector.

“We believe the biggest challenges in society can be addressed using technology and innovation. These awards are just one way we can recognise, celebrate and support startups developing and using technology as a force for good.”

Ed Evans, chief executive of Social Tech Trust, had this to say of the awards: “Vodafone Techstarter is a hugely powerful platform that showcases the potential of partnership and demonstrates how cross-sector organisations can work together to create something truly inspiring.”

For more information on how you can work with LettUs Grow or support their growth, contact Managing Director Charlie Guy on

Mendelian receives over £500,000 from InnovateUK to help identify patients with rare or hard to diagnose conditions

Mendelian, a UK healthtech startup, has received a grant from Innovate UK to build solutions that will assist GPs in identifying NHS patients who potentially have rare or hard to diagnose conditions and diseases. The grant is being used to implement the company’s specialised screening system, which provides augmented intelligence and data analysis to deliver the fast, accurate and automated identification of patients who may fit the rare disease or difficult to diagnose categories. Once the technology has analysed a patient’s symptoms, they are then flagged to the GP who has various options, including referring the patient to a specialist or recommending further analysis and testing.

Research has shown that in the UK it takes an average of 5.6 years, eight clinicians (including four specialists) and three misdiagnoses before the correct rare disease is identified*. A further health economics report commissioned and released in November last year by Mendelian revealed that over the last 10 years, rare disease patients while undiagnosed have cost the NHS in excess of over £3.4 billion.

Dr. Peter Fish, Head of Clinical Partnerships at Mendelian said: “It’s clear that this ‘diagnostic odyssey’ is not only causing patients distress and emotional turmoil but is also extremely frustrating for clinicians, as well as costly for healthcare systems and ultimately tax-payers. To help solve this pressing issue we’re delighted to be providing a solution within the NHS, for not only rare disease patients, but also those with hard to diagnose conditions. Crucially, Mendelian’s technology is being implemented at the general practice stage, right at the beginning of the patient journey with the aim of identifying these conditions as early on as possible.”

Piers Ricketts, Chief Executive at the Eastern Academic Health Science Network, said:

“We are delighted to support Mendelian as part of our work into rare diseases. With over 3 million rare disease patients in the UK, innovative technologies using data analytics and machine learning like this are increasingly vital in ensuring that these conditions are diagnosed earlier to provide more targeted and personalised treatment for patients.”

The total budget for the project is £940,000 with over £500,000 of this awarded to Mendelian by Innovate UK – a non-departmental public body and the UK’s innovation agency – in order to develop and implement the technology. The project is set to run over the next two years with the first trial currently taking place in Hertfordshire, in partnership with the Eastern Academic Health Science Network (EAHSN) and NHS East and North Hertfordshire Clinical Commissioning Group (CCG).** Following this, the technology will potentially be rolled out to further areas in the UK, as well as globally in the near future.


** The trial will analyse pseudonymised electronic medical records to find patients that should be investigated further for rare or hard to diagnose diseases and the protection of patient data will be prioritised at all times throughout.

About Mendelian

Mendelian is a technology company building the world’s largest repository of information to help accelerate the diagnosis of rare diseases. The company is a team of eight based in London, with a wealth of experience across a range of complimentary disciplines including business, machine learning, data science, design and medicine. Currently Mendelian’s free service has been used by clinicians and specialists (geneticists, pediatricians, neurologists, cardiologists) across a range of disciplines in more than 150 countries.  ­­­
For further information, interviews and images, please contact:

Ozo Innovations secured £600k Grant funding from UK Government

Oxford, UK, January 30 2019: Ozo Innovations (Ozo) announces that it has secured over £600,000 project funding from the Department of Business Energy Industrial Strategy (BEIS) Industrial Energy Efficiency Accelerator (IEEA) Programme managed by the Carbon Trust and Jacobs.

The IEEA aims to lower costs and increase the number of available energy efficient technologies for a range of industrial sectors, through demonstration of near to market innovations. This will help to reduce carbon emissions and improve the competitiveness of UK industry. The funding will enable Ozo to substantiate the significant energy savings that could be achieved by implementing Ozo’s eloclear® hygiene process.

The project hopes to demonstrate that it is possible to:

  • remove hot water from the food factory hygiene process;
  • reduce the total volume of water used; and
  • achieve robust high-quality hygiene outcomes.

The food industry’s reliance on hot water for hygiene means that it is an energy intensive process, yet it is often an unrecognised hygiene cost, as utilities spend is managed separately from hygiene chemicals, labour and testing costs.

Ozo substitutes cold electrolysed water for hot water, which requires significantly less power to produce. Using “cold water” for hygiene further benefits food processors that operate in chilled environments as it reduces condensation and removes the energy costs associated with re-chilling spaces that become warm when cleaned with hot water. The business has been working with leading UK food companies to optimise the technology and help businesses be more sustainable and competitive.

This demonstration project will compare the energy saving benefits of eloclear over the current industry standard of hot water based, multi-step chemical cleaning, across a number of standard hygiene procedures. Results will be published once the project is complete, in around 18 months’ time.

The trial site chosen is a leading maker of sandwiches, recognising that the “food-to-go” standards are some of the most demanding in the food industry.

“Consumers are recognising that their food choices are putting the planet under pressure. We use 70% of our fresh water for food production. Hygiene is an area, which offers an opportunity to save energy and water whilst maintaining or improving standards. This is good for everyone, as better hygiene means we can achieve longer shelf life, reduce food waste and maintain the safety of our food. We are delighted to have the support of Carbon Trust and Jacobs to demonstrate the energy credentials of eloclear,”

said Rowan Gardner, CEO of Ozo.

Paul Huggins, Director Innovation, the Carbon Trust:

“This exciting technology could have a major impact throughout the food industry, radically simplifying the way the sector carry out their hygiene processes. We are looking forward to working with Ozo, and scrutinising both the technical performance and energy saving credentials of the technology.”

About Ozo Innovations  

Ozo develops and markets novel products for effective cleaning and disinfection, and food safety applications. The company’s systems transform food grade salt and water into powerful disinfectants using electrolysis. The company works with leading food companies, authorities and retailers to prove the safety and efficiency of their approach. Ozo delivers benefits that are significant and quantifiable and add competitive advantage to the food industry:

  • Additional production capacity – saving time cleaning and achieving more robust hygiene outcomes delivers more time for production
  • Resource savings – Reducing energy, water, effluent and manpower spent on food hygiene and facilities cleaning and disinfections
  • Significant new value opportunities – through process innovation, product quality and risk reduction

Ozo’s products are in situ biocides for the purposes of EU (528/2012) Biocide Product Regulations (BPR). The company is listed on Article 95 as a provider of active substances.

eloclear® is a registered Trade Mark of Ozo Innovations Ltd.

About IEEA 

  • The IEEA is four-year, £9.2m programme funded by BEIS. The Carbon Trust and Jacobs manage the programme, in addition to providing project management and incubation assistance to the participating companies. The IEEA is designed to support partnerships between developers of innovative energy efficient technologies and industrial companies willing to test technologies on-site. The programme is open to projects from all UK industry sectors that can demonstrate either a novel technology (targeting Technology Readiness Level 5-8), or the use of an established technology in a novel way.
  • The BEIS IEEA allows promising innovators to demonstrate their technology in an operational environment and increase confidence from potential users. The BEIS IEEA also provides forward-looking industrial companies with an opportunity to implement pioneering technologies with decreased risk and capital cost.

For further information, please contact:
Lisa Holloway
Marketing Manager
Ozo Innovations
Tel: +44-(0)-1865-891012